Effect of nimesulide on the serum levels of hyaluronan and stromelysin-1 in patients with osteoarthritis: A pilot study

International Journal of Clinical Practice, Supplement

Volumn , Issue 144, 2004, Pages 13-19

  Bevilacqua, Maurizio ^a   Devogelaer, Jean Pierre ^b   Righini, Velella ^a   Famaey, Jean Pierre ^c,d   Manicourt, Daniel Henri ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c FREE UNIVERSITY OF BRUSSELS   (Belgium)

^d Department of Therabel Pharma ^*  (Belgium)

Author keywords

Hyaluronan (HA); Ibuprofen; Nimesulide; Non steroidal anti inflammatory drugs; Osteoarthritis; Stromelysin 1 (MMP 3)

Indexed keywords

GLYCOPROTEIN GP 39; HYALURONIC ACID; IBUPROFEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; YKL 40;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; EPIGASTRIC PAIN; HEMATOCHEZIA; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; OSTEOARTHRITIS; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PRURITUS; SINGLE BLIND PROCEDURE;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; FEMALE; HUMANS; HYALURONIC ACID; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; OSTEOARTHRITIS; PILOT PROJECTS; SINGLE-BLIND METHOD; SULFONAMIDES;

EID: 10444285265     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Sandy JD. Proteolytic degradation of normal and osteoarthritic cartilage. In: Brandt KD, Doherty M, Lohmander LS, Eds. Osteoarthritis, 2nd edn. Oxford University Press, 2003; 82-92.
2. Clark IM, Murphy G. Matrix Proteinases. In: Seibel MJ, Robins SP, Bilezikian JP, Eds. Dynamics of Bone and Cartilage Metabolism. San Diego: Academic Press, 1999; 137-150.
3. Manicourt DH, Fujimoto N, Obata K, Thonar EJ-M. Serum levels of collagenase, stromelysin-1 and TIMP-1. Age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis. Arthritis Rheum 1994; 37: 1774-1783.
4. Yoshihara Y, Nakamura H, Obata K et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000; 59: 455-461.
5. van den Berg WB, van der Kraan PM, van Beuringen HM. Synovial mediators of cartilage damage and repair in osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, Eds. Osteoarthritis, 2nd edn. Oxford University Press, 2003; 147-155.
6. Ayral X, Dougados M, Listrat V et al. Arthroscopic evaluation of chondropathy in osteoarthritis of the knee. J Rheumatol 1996; 23: 698-706.
7. Ayral X, Pickering EH, Woodworth TJ et al. Synovitis predicts the arthroscopic progression of medial tibiofemoral knee osteoarthritis. Ann Rheum Dis 2001; 60: 57 (Abstract).
8. Sharif M, George E, Shepstone L et al. Serum hyaluronic acid level as a predictor of disease progression in osteoarthritis of the knee. Arthritis Rheum 1995; 38(6): 760-767.
9. Spector TD, Hart DJ, Nandra D et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997; 40: 723-727.
10. Volck B, Johansen JS, Stoltenberg M et al. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 2001; 9: 203-214.
11. Knorr T, Obermayr F, Bartnik E et al. YKL-39 (chitinase 3-like protein 2), but not YKL-40 (chitinase 3-like protein 1), is up regulated in osteoarthritic chondrocytes. Ann Rheum Dis 2003; 62: 995-998.
12. Dubois RN, Abramson SB, Crofford L et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-1073.
13. Amin AR, Attur M, Patel RN et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest 1997; 99: 1231-1237.
14. Huskisson EC, Berry H, Gishen P et al. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis. J Rheumatol 1995; 22: 1941-1946.
15. Ding C. Do NSAIDs affect the progression of osteoarthritis? Inflammation 2002; 26: 139-142.
16. Peterfy CG. Magnetic Resonance Imaging. In: Brandt KD, Doherty M, Lohmander LS, Eds. Osteoarthritis, 2nd edn. Oxford University Press, 2003; 433-451.
17. Thonar EJ-M, Lenz ME, Masuda K, Manicourt DH. Body Fluid Markers of Cartilage Metabolism. In: Seibel MJ, Robins SP, Bilezikian JP, Eds. Dynamics of Bone and Cartilage Metabolism. San Diego: Academic Press, 1999; 453-464.
18. Lohmander LS, Poole AR. Defining and validating the clinical role of molecular markers in osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, Eds. Osteoarthritis, 2nd edn. Oxford University Press, 2003; 468-477.
19. Miralpeix M, Camacho M, Lopez-Belmonte J et al. Selective induction of cyclo-oxygenase-2 activity in the permanent human endothelial cell line HUV-EC-C: biochemical and pharmacological characterization. Br J Pharmacol 1997; 121(2): 171-180.
20. Warner TD, Giuliano F, Vojnovic I et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563-7568.
21. Manicourt DH, Triki R, Fukuda K et al. Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum 1993; 36: 490-499.
22. Harvey S, Weisman M, O'Dell J et al. Chondrex: new marker of joint disease. Clin Chem 1998; 44: 509-516.
23. Laurent TC, Laurent UB, Fraser JR. Serum hyaluronan as a disease marker. Ann Med 1996; 28: 241-253.
24. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 1997; 242: 27-33.
25. Sharma L, Hurwitz DE, Thonar EJ et al. Knee adduction moment, serum hyaluronan level, and disease severity in medial tibiofemoral osteoarthritis. Arthritis Rheum 1998; 41: 1233-1240.
26. Meyer FA, Yaron I, Mashiah V, Yaron M. Effect of diclofenac on prostaglandin E and hyaluronic acid production by human synovial fibroblasts stimulated with interleukin-1. Br J Clin Pharmacol 1989; 28: 193-196.
27. Facino RM, Carini M, Aldini G. Antioxidant activity of nimesulide and its main metabolites. Drugs 1993; 46(Suppl 1): 15-21.
28. Dahl LB, Dahl IM, Engstrom-Laurent A, Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis 1985; 44: 817-822.
29. Saari H, Sorsa T, Konttinen YT. Reactive oxygen species and hyaluronate in serum and synovial fluid in arthritis. Int J Tissue React 1990; 12: 81-89.
30. Kvam BJ, Fragonas E, Degrassi A et al. Oxygen-derived free radical (ODFR) action on hyaluronan (HA), on two HA ester derivatives, and on the metabolism of articular chondrocytes. Exp Cell Res 1995; 218: 79-86.
31. Pelletier JP, Martel-Pelletier J. Effects of nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoarthritic cartilage. Drugs 1993; 46(Suppl 1): 34-39.
32. Kullich WC, Niksic F, Klein G. Effect of nimesulide on metalloproteinases and matrix degradation in osteoarthritis: a pilot clinical study. Int J Clin Pract 2002; Suppl 128: 24-29.
33. Sadowski T, Steinmeyer J. Effects of non-steroidal antiinflammatory drugs and dexamethasone on the activity and expression of matrix metalloproteinase-1, matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by bovine articular chondrocytes. Osteoarthritis Cartilage 2001; 9: 407-415.
34. Volck B, Ostergaard K, Johansen JS et al. The distribution of YKL-40 in osteoarthritic and normal human articular cartilage. Scand J Rheumatol 1999; 28: 171-179.